6,000 Shares in BioNTech SE (NASDAQ:BNTX) Purchased by Mirabaud & Cie SA

Mirabaud & Cie SA purchased a new stake in shares of BioNTech SE (NASDAQ:BNTX) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 6,000 shares of the company’s stock, valued at approximately $684,000.

Other large investors also recently made changes to their positions in the company. Marshall Wace LLP bought a new stake in shares of BioNTech during the second quarter worth $2,892,000. Point72 Asset Management L.P. lifted its position in shares of BioNTech by 283.5% during the 2nd quarter. Point72 Asset Management L.P. now owns 461,711 shares of the company’s stock valued at $37,103,000 after acquiring an additional 341,311 shares during the period. Caxton Associates LP bought a new position in shares of BioNTech during the 2nd quarter worth about $682,000. Employees Retirement System of Texas increased its holdings in shares of BioNTech by 15.7% during the second quarter. Employees Retirement System of Texas now owns 30,388 shares of the company’s stock valued at $2,442,000 after acquiring an additional 4,115 shares in the last quarter. Finally, Deerfield Management Company L.P. Series C lifted its stake in shares of BioNTech by 4.3% in the second quarter. Deerfield Management Company L.P. Series C now owns 594,000 shares of the company’s stock valued at $47,734,000 after buying an additional 24,426 shares in the last quarter. Institutional investors own 15.52% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on BNTX shares. BMO Capital Markets reiterated an “outperform” rating on shares of BioNTech in a research note on Monday, December 2nd. The Goldman Sachs Group upgraded shares of BioNTech from a “neutral” rating to a “buy” rating and upped their target price for the stock from $90.00 to $137.00 in a research report on Friday, November 8th. Canaccord Genuity Group raised their price target on BioNTech from $171.00 to $171.44 and gave the stock a “buy” rating in a research report on Wednesday, November 27th. Morgan Stanley upgraded shares of BioNTech from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $93.00 to $145.00 in a report on Tuesday, September 24th. Finally, Evercore ISI raised shares of BioNTech from an “in-line” rating to an “outperform” rating and lifted their price target for the company from $110.00 to $125.00 in a research report on Tuesday, November 19th. Three analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $142.72.

BioNTech Trading Up 4.8 %

NASDAQ:BNTX opened at $117.25 on Wednesday. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. The firm has a market cap of $28.11 billion, a PE ratio of -55.83 and a beta of 0.18. BioNTech SE has a 12-month low of $76.53 and a 12-month high of $131.49. The stock has a fifty day moving average price of $114.97 and a 200 day moving average price of $105.25.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings results on Monday, November 4th. The company reported $0.81 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.26) by $2.07. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The firm had revenue of $1.24 billion during the quarter, compared to analysts’ expectations of $514.08 million. During the same period in the prior year, the company posted $0.73 earnings per share. The firm’s revenue for the quarter was up 38.9% on a year-over-year basis. Sell-side analysts anticipate that BioNTech SE will post -3.77 earnings per share for the current fiscal year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.